ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Actinium Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.32+0.19 (+16.81%)
Close on Oct 19, 2026
- Market cap
- $41.46M
- P/E (TTM)
- 3.7
- Dividend yield
- –
Actinium Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Other Revenue | $90.00K | – | $81.00K | $1.03M | 100.0% | – |
| Grant Revenue [Member] | – | $100.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Actinium Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.